D. Rubinow

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
David R. Rubinow, D. R Rubinow, D. R. Rubinow, Dr Rubinow, D R Rubinow, David R Rubinow, David Rubinow, Davida. Rubinow, D Rubinow, D. Rubinow
Publication record
381 papers · 23,111 citations · H-index 83

PAPERS

Divergent Transcriptomic Effects of Allopregnanolone in Postpartum Depression
20231 citationsauthor #5
Autonomic and Depression Symptoms in Parkinson’s Disease: Clinical Evidence for Overlapping Physiology
202213 citationsauthor #4
Transcriptome-wide association study for postpartum depression implicates altered B-cell activation and insulin resistance
202224 citationsauthor #4
Baseline anxiety-sensitivity to estradiol fluctuations predicts anxiety symptom response to transdermal estradiol treatment in perimenopausal women - A randomized clinical trial.
202221 citationsauthor #8
Effect of tACS on prefrontal neural activity is menstrual phase dependent in patients with premenstrual dysphoric disorder
20224 citationsauthor #2
Effects of acute estradiol and progesterone on perimenstrual exacerbation of suicidal ideation and related symptoms: a crossover randomized controlled trial
202233 citationsauthor #7
Subgenual cingulate resting regional cerebral blood flow in premenstrual dysphoric disorder: differential regulation by ovarian steroids and preliminary evidence for an association with expression of ESC/E(Z) complex genes
20215 citationsauthor #9
One Small Step for PMDD, One Large Step for Affective Disorders.
20219 citationsauthor #1
Comment on "Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids".
20210 citationsauthor #1
Disinhibition of right inferior frontal gyrus underlies alpha asymmetry in women with low testosterone.
20217 citationsauthor #2
In search of sex-related mediators of affective illness
202110 citationsauthor #2
The Cortisol and ACTH response to Dex/CRH testing in Women with and without Perimenopausal Depression.
20218 citationsauthor #7
Reward-Based Decision-Making Engages Distinct Modes of Cross-Frequency Coupling.
202127 citationsauthor #4
In search of sex-related mediators of affective illness
20210 citationsauthor #2
The short-term effects of estradiol, raloxifene, and a phytoestrogen in women with perimenopausal depression.
202117 citationsauthor #11
Pubertal sex hormones control transcriptional trajectories in the medial preoptic area
20213 citationsauthor #12
Altered estradiol-dependent cellular Ca2+ homeostasis and endoplasmic reticulum stress response in Premenstrual Dysphoric Disorder
202118 citationsauthor #9
Perimenopausal transdermal estradiol replacement reduces serum HDL cholesterol efflux capacity but improves cardiovascular risk factors.
20208 citationsauthor #6
Transcranial Alternating Current Stimulation Differently Modulates Brain Activity in Depressed Patients and Healthy Controls
20200 citationsauthor #5
Reduction in Depressive Symptoms Over the First 24 Hours in Patients With PPD Treated With the Neuroactive Steroid Brexanolone Injection
20201 citationsauthor #5
IL-6 Response to Psychosocial Stress Predicts 12-month Changes in Cardiometabolic Biomarkers in Perimenopausal Women.
20207 citationsauthor #5
Test-statistic inflation in methylome-wide association studies
202023 citationsauthor #4
In vitro model of perimenopausal depression implicates steroid metabolic and proinflammatory genes
202014 citationsauthor #4
Reproductive Hormones Regulate Affect and Reward Circuit Function in Women
20203 citationsauthor #8
Theta Oscillations Increase During Negative Experiences in Patients in a Depressive Episode
20200 citationsauthor #6
Depression and the Perimenopause Transition: A Prospective Longitudinal Study
20200 citationsauthor #9
HPA axis regulation and epigenetic programming of immune-related genes in chronically stressed and non-stressed mid-life women.
202027 citationsauthor #7
182. Differential Gene Expression in Response to Estradiol Withdrawal in Perimenopausal Depression
20190 citationsauthor #3
Trial of SAGE-217 in Patients with Major Depressive Disorder.
2019180 citationsauthor #10
Effects of perimenopausal transdermal estradiol on self-reported sleep, independent of its effect on vasomotor symptom bother and depressive symptoms.
201923 citationsauthor #4
SUN-197 Differential Gene Expression in Response to Estradiol Withdrawal in Perimenopausal Depression
20190 citationsauthor #3
Health-related quality of life in a Phase 2, randomized, placebo-controlled trial of the GABA(A)R modulator SAGE-217 in major depressive disorder
20191 citationsauthor #11
Double-blind, randomized pilot clinical trial targeting alpha oscillations with transcranial alternating current stimulation (tACS) for the treatment of major depressive disorder (MDD)
2019179 citationsauthor #6
Brexanolone iv efficacy in postpartum depression in three pivotal trials: montgomery‐åsberg depression rating scale assessment: 86
20192 citationsauthor #7
The Effect of Perimenopausal Transdermal Estradiol and Micronized Progesterone on Markers of Risk for Arterial Disease.
201914 citationsauthor #2
P.309 Double-blind, randomized, placebo-controlled trials of brexanolone injection in postpartum depression: analysis of ham-d depression subscales and individual symptom items
20190 citationsauthor #6
The gamma-aminobutyric acid type A receptor positive allosteric modulators brexanolone injection and SAGE-217 in the treatment of mood disorders: Results from recent placebo-controlled studies
20190 citationsauthor #8
A case study of weekly tACS for the treatment of major depressive disorder
201937 citationsauthor #2
181. Variations in Sex-Steroid Regulated Genes: Ovarian Steroid Hormones Modulate Working-Memory Related Brain Function in Women
20190 citationsauthor #7
F73. Efficacy of Brexanolone Injection in Subjects With Postpartum Depression With and Without Baseline Antidepressant Therapy: Insights From an Integrated Analysis of Three Pivotal Trials
20190 citationsauthor #6
SA45APPLYING GENETIC RISK SCORES TO AN ETHNICALLY DIVERSE SAMPLE OF POSTPARTUM WOMEN
20190 citationsauthor #4
ADVERSE LIFE EVENTS, PSYCHIATRIC COMORBIDITY, AND BIOLOGICAL PREDICTORS OF POSTPARTUM DEPRESSION IN AN ETHNICALLY DIVERSE SAMPLE OF POSTPARTUM WOMEN
20190 citationsauthor #6
Brexanolone injection for post-partum depression treatment - Authors' reply.
20191 citationsauthor #4
SAGE-217 in major depressive disorder: A multicenter, randomized, double-blind, Phase 2 placebo-controlled trial
20195 citationsauthor #9
180. Premenstrual Dysphoric Disorder (PMDD): Neuroanatomical Hubs and Cellular Substrates of Risk
20190 citationsauthor #11
Brexanolone iv, a GABA-A receptor modulator, in postpartum depression: Pooled analysis of HAM-D sub-items
20191 citationsauthor #6
Brexanolone Injection in Postpartum Depression: 2 Multicenter, Double-blind, Randomized, Placebo-controlled Phase 3 Trials
201919 citationsauthor #6
Transdermal estradiol for postpartum depression: results from a pilot randomized, double-blind, placebo-controlled study
201921 citationsauthor #6
S199. Neural and Affective Effects of Reproductive Steroid Manipulation in Reproductive-Related Mood Disorders
20190 citationsauthor #8
Phase 3 Study Evaluating Brexanolone, a GABAA Receptor Modulator, in Moderate Postpartum Depression [25H]
20181 citationsauthor #4
Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial
2018177 citationsauthor #2
The role of ovarian steroids in affective disorders
201823 citationsauthor #4
Early Life Abuse Moderates the Effects of Intranasal Oxytocin on Symptoms of Premenstrual Dysphoric Disorder: Preliminary Evidence From a Placebo-Controlled Trial
201813 citationsauthor #4
Progesterone and plasma metabolites in women with and in those without premenstrual dysphoric disorder
20186 citationsauthor #4
Emotion-related impulsivity and rumination predict the perimenstrual severity and trajectory of symptoms in women with a menstrually related mood disorder.
201824 citationsauthor #5
F122. The Neuronal Stem Cell Transcriptome of Premenstrual Dysphoric Disorder
20180 citationsauthor #6
S100. Efficacy and Safety of Brexanolone IV Across Phase 2/3 Studies: A First-In-Class GABAA Receptor Positive Allosteric Modulator for Postpartum Depression
20183 citationsauthor #6
Safety of Estradiol Treatment in Perimenopausal Asymptomatic Women-Reply.
20181 citationsauthor #1
Sex differences and the neurobiology of affective disorders
2018210 citationsauthor #1
Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials.
2018449 citationsauthor #6
Is there a role for reproductive steroids in the etiology and treatment of affective disorders?
201836 citationsauthor #1
O46. SAGE-217 a First in Class GABAA Receptor Positive Allosteric Modulator in Major Depressive Disorder: A Multicenter, Randomized, Double-Blind, Phase 2 Placebo-Controlled Trial
20181 citationsauthor #9
Corrigendum: Hormonal gain control of a medial preoptic area social reward circuit
20174 citationsauthor #29
The steroid metabolome in women with premenstrual dysphoric disorder during GnRH agonist-induced ovarian suppression: effects of estradiol and progesterone addback
201740 citationsauthor #9
Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression
2017133 citationsauthor #6
Perimenopausal depression and early menopause: cause or consequence?
20175 citationsauthor #3
In immune defense: redefining the role of the immune system in chronic disease
201720 citationsauthor #2
Treatment of premenstrual dysphoria with continuous versus intermittent dosing of oral contraceptives: Results of a three‐arm randomized controlled trial
201731 citationsauthor #5
Depression during the menopause transition: impact on quality of life, social adjustment, and disability
201750 citationsauthor #7
Hormonal gain control of a medial preoptic area social reward circuit
2017245 citationsauthor #11
Clinical phenotypes of perinatal depression and time of symptom onset: analysis of data from an international consortium.
2017237 citationsauthor #34
893. Adverse Life Events, Psychiatric Comorbidity, and Biological Predictors of Postpartum Depression in an Ethnically Diverse Sample of Postpartum Women
20170 citationsauthor #7
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
2017344 citationsauthor #12
Protocol Title: The effects of acute withdrawal of estradiol on mood symptoms in women with
20170 citationsauthor #2
Toward the Reliable Diagnosis of DSM-5 Premenstrual Dysphoric Disorder: The Carolina Premenstrual Assessment Scoring System (C-PASS).
201785 citationsauthor #7
Premenstrual Dysphoric Disorder Symptoms Following Ovarian Suppression: Triggered by Change in Ovarian Steroid Levels But Not Continuous Stable Levels.
2017162 citationsauthor #8
505. Lymphoblastoid Cell Lines from Women with Premenstrual Dysphoric Disorder Differ in Genetic, mRNA, and Protein Expression Profiles Compared with Asymptomatic Controls
20171 citationsauthor #9
HPA axis reactivity to pharmacologic and psychological stressors in euthymic women with histories of postpartum versus major depression
201711 citationsauthor #6
Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition
2016116 citationsauthor #2
Histories of abuse predict stronger within-person covariation of ovarian steroids and mood symptoms in women with menstrually related mood disorder.
201655 citationsauthor #2
Cardiovascular, hemodynamic, neuroendocrine, and inflammatory markers in women with and without vasomotor symptoms
201642 citationsauthor #2
Sex, Drugs, and the Neurobiology of the Placebo Effect.
20161 citationsauthor #1
History of postpartum depression in a clinic-based sample of women with premenstrual dysphoric disorder.
201626 citationsauthor #4
Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder
201683 citationsauthor #20
The ESC/E(Z) complex, an effector of response to ovarian steroids, manifests an intrinsic difference in cells from women with Premenstrual Dysphoric Disorder
201674 citationsauthor #7
Sex differences in visuospatial abilities persist during induced hypogonadism.
201616 citationsauthor #7
Reproductive Steroid Regulation of Mood and Behavior.
2016168 citationsauthor #5
Naturally Occurring Changes in Estradiol Concentrations in the Menopause Transition Predict Morning Cortisol and Negative Mood in Perimenopausal Depression
201666 citationsauthor #3
Taking Care of Our Own: A Multispecialty Study of Resident and Program Director Perspectives on Contributors to Burnout and Potential Interventions
201699 citationsauthor #7
The Effects of Trauma History and Prenatal Affective Symptoms on Obstetric Outcomes.
201640 citationsauthor #4
5α-Reductase Inhibition Prevents the Luteal Phase Increase in Plasma Allopregnanolone Levels and Mitigates Symptoms in Women with Premenstrual Dysphoric Disorder
2016128 citationsauthor #2
Protocol Title: The effects of acute withdrawal of estradiol on mood symptoms in women with perimenopausal depression
20150 citationsauthor #2
DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA’s antidepressant action
201516 citationsauthor #4
Effects of Estradiol Withdrawal on Mood in Women With Past Perimenopausal Depression: A Randomized Clinical Trial.
2015195 citationsauthor #9
9a. Reproductive Steroids and Depression: The Brain in Context
20150 citationsauthor #1
Heterogeneity of postpartum depression: a latent class analysis.
2015207 citationsauthor #31
CNS volume 20 issue 1 Cover and Front matter
20150 citationsauthor #9
DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA’s antidepressant action
20151 citationsauthor #4
Maternally responsive neurons in the bed nucleus of the stria terminalis and medial preoptic area: Putative circuits for regulating anxiety and reward.
201533 citationsauthor #2
Erratum to: DHEA metabolism to the neurosteroid androsterone: a possible mechanism of DHEA’s antidepressant action
201566 citationsauthor #4

TIMELINE

1951 0 citations

1977 5 citations

1980 16 citations

1981 26 citations

1982 159 citations

1983 760 citations

1984 158 citations

1985 239 citations

1986 713 citations

1987 485 citations

1988 586 citations

1989 611 citations

1990 642 citations

1991 1,050 citations

1992 325 citations

1993 600 citations

1994 328 citations

1995 161 citations

1996 530 citations

1997 891 citations

1998 1,422 citations

1999 501 citations

2000 1,632 citations

2001 150 citations

2002 784 citations

2003 1,054 citations

2004 545 citations

2005 707 citations

2006 316 citations

2007 798 citations

2008 112 citations

2009 72 citations

2010 935 citations

2011 157 citations

2012 49 citations

2013 502 citations

2014 526 citations

2015 595 citations

2016 914 citations

2017 1,368 citations

2018 944 citations

2019 483 citations

2020 83 citations

2021 104 citations

2022 95 citations

2023 1 citations

Unknown 0 citations

D. Rubinow

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT